Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Kenneth Bilchick Added: 2 weeks ago
HRS Congress 2026 — Dr Kenneth Bilchick (UVA Heart & Vascular Center, Charlottesville, VA, US) joins us to discuss findings from a study examining whether the protective effect of glucagon-like peptide-1 (GLP-1) receptor agonists on atrial fibrillation risk operates independently of weight loss and survival.Interview Questions:What is the current understanding of how GLP-1 receptor agonists may… View more
Author(s): Riccardo Cappato , Rui Providencia Added: 1 year ago
What updates do ECAS recommend for catheter ablation of atrial fibrillation?In this short interview, Prof Riccardo Cappato (IRCCS Humanitas Research Hospital, Milan, IT) and Prof Rui Providência (St Bartholomew's Hospital, London, UK) discuss new guidelines released by ECAS on catheter ablation for atrial fibrillation (AF). Prof Cappato and Prof Providência explain the need for an updated and… View more
Author(s): Ulrich Schotten Added: 1 week ago
HRS Congress 2026 — Prof Ulrich Schotten (Maastricht University, Maastricht, NL) joins us to discuss new findings from the NOAH-AFNET 6 trial examining the distribution of atrial fibrillation burden, its relationship to clinical outcomes, and the effectiveness and safety of anticoagulation based on device reports.NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial… View more
Author(s): Renato D Lopes Added: 1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed… View more
Author(s): Manesh R Patel , Harriette Van Spall Added: 1 year ago
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the… View more